Premium
BCL‐2 protein regulation of apoptosis in diabetic cardiomyopathy
Author(s) -
Van Dalfsen Kelsey M,
Del Gaizo Moore Victoria
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.835.6
Subject(s) - apoptosis , diabetic cardiomyopathy , diabetes mellitus , downregulation and upregulation , function (biology) , medicine , bcl 2 family , cardiomyopathy , endocrinology , microbiology and biotechnology , chemistry , cancer research , programmed cell death , biology , heart failure , biochemistry , gene
Diabetic cardiomyopathy (DCM) is a complication of diabetes that affects heart function and contributes to mortality. Hyperglycemia has been identified as a major factor in DCM's development, and is believed to act in part by promoting apoptosis. Given the integral role BCL‐2 family proteins have in controlling apoptosis, the effects of hyperglycemia on BCL‐2 proteins are being studied. Using cultured cardiomyocytes and primary cells isolated from hyperglycemic chick embryos, cardiomyocyte apoptosis has been confirmed as a result of hyperglycemia. Furthermore, protein levels of various BCL‐2 family proteins have been observed to change under hyperglycemic conditions. Taken together, results from this study will contribute to the understanding of the biochemical basis of DCM and aid in the identification of potential therapeutic targets. Elon University Undergraduate Research Program, Chemistry Department, and Provost Award to VDGM.